SDTMIG: The Study Data Tabulation Model Implementation Guide (SDTMIG) for human clinical trials guides users on the organization, structure, and format of standard clinical study tabulation datasets for interchange between organizations or to be submitted to a regulatory authority. The following videos introduce you to the SDTMIG and the SDTM, which used together serve as a map that orients you on how your data fits into the standard.
A Study Data Tabulation Model Implementation Guide (SDTMIG) is developed in reference to a specific SDTM model. However, the SDTM is cumulative – each new release builds on the previous model. Therefore, the models are backward compatible. For example, SDTMIG-AP v1.0 was developed in reference to SDTM v1.4, but it may be used in a submission that uses SDTM v1.7.
Implementers should be aware that if they are referencing a model for which the IG was not originally developed, variables may have been added or deprecated from the model. In addition to models and implementation guides, conformance rules have been developed, which help to ensure that generated data structures conform to the standards. These rules aim to identify all conformance rules and case logic from the SDTM and SDTMIG, classifying and codifying them in a form that supports quality processes and tool development.
Therapeutic Area User Guides
Therapeutic Area User Guides (TAUGs) extend the Foundational Standards to represent data that pertains to specific disease areas. TAUGs include disease-specific metadata, examples and guidance on implementing CDISC standards for a variety of uses, including global regulatory submissions. The following video will introduce you to TAUGs and how they relate to CDISC Foundational Standards.
Controlled Terminology is the set of codelists and valid values used with data items within CDISC-defined datasets. The following video introduces you to CDISC Controlled Terminology and how it is used with CDISC standards.
Traceability is a fundamental element of data quality and a requirement for studies submitted to regulatory authorities. From data collection to final analysis, traceability plays a crucial role in ensuring the integrity of source data and in reinforcing clinical research results. The following video provides an introduction to implementing traceability in CDISC-compliant studies.
CDISC standards are required or recommended by several global regulatory agencies. Standardized data enables regulators to streamline the review process with a more consistent use of analysis tools to better view drug data and highlight areas of concern. The following video introduces you to regulatory requirements and the use of CDISC standards.
Team Guiding Principles
Standards in Development
For current versions of the standards, please visit the Standards Home Page.
|Standard Sort descending||Release Notes||Projected Publication|
|ADaM Examples of Traceability||
Resolving Public Comments.
|ADaM Oncology Examples||
|Analysis Results Standard v1.0||2022|
|Medical Devices Conformance Rules||
|Safety User Guide v1.0||2022|
For current versions of the Therapeutic Area (TA) standards, please visit the TA Home Page.
|Therapeutic Area Sort descending||Release Notes||Projected Publication|
|Diabetes Type 1 Therapeutic Area User Guide - Screening, Staging and Monitoring of Pre-clinical Type 1 Diabetes||
Preparing for Publication
|Pediatrics User Guide v1.0||2022|
|Rare Diseases Therapeutic Area User Guide||Q1 2022|
|Traditional Chinese Medicine - Acupuncture Therapeutic Area User Guide v1.0||
Preparing for Public Review.